A practical reference on research compound: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-05. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
The overlying beds were presumably the source of the copper, which precipitated as turquoise in nodules, horizontal seams, or vertical joints in the sandstone beds. The classical Iranian deposits are found in sandstones and limestones of Tertiary age that were intruded by apatite-rich porphyritic trachytes and mafic rock. Supergene alteration fractured the rock and converted some of the minerals in the rock to alunite, which freed aluminum and phosphate to combine with copper from oxidized copper sulfides to form turquoise. This process took place at a relatively shallow depth, and by 1965 the mines had "bottomed" at a depth averaging just 9 meters (30 ft) below the surface. Turquoise deposits are widespread in North America. Some deposits, such as those of Saguache and Conejos Counties in Colorado or the Cerrillos Hills in New Mexico, are typical supergene deposits formed from copper porphyries. The deposits in Cochise County, Arizona are found in Cambrian quartzites and geologically young granites and go down at least as deep as 54 meters (177 ft).
Testing during and for many weeks after a hemolytic episode will lead to false-negative results, as the G6PD-deficient RBC will have been excreted, and the young RBC (reticulocyte) will not yet be G6PD deficient. False-negative results will also be likely following any blood transfusions. For this reason, many hospitals wait three months after a hemolytic episode before testing for G6PD deficiency. Females should have their G6PD activity measured by a quantitative assay to avoid being misclassified by screening tests.
The report derived its estimate of indirect deaths using a calculation from the Geneva Declaration of Secretariat which estimates that for every person directly killed by war, four more die from the indirect consequences of war. The U.S. Constitution and U.S. law prohibits the use of torture, yet such human rights violations occurred during the war on terror under the euphemism "enhanced interrogation." In 2005, The Washington Post and Human Rights Watch (HRW) published revelations concerning CIA flights and "black sites", covert prisons operated by the CIA. The term "torture by proxy" is used by some critics to describe situations in which the CIA and other U.S. agencies have transferred suspected terrorists to countries known to employ torture.
Sources: en.wikipedia.org
== Notable people with Alport syndrome == Sam Clarke, British filmmaker Shae Hutchinson, Norwich City Football Club Under-23's player Christopher Kelsall, drummer for band Mirrortalk Ellie Kugler, American Kidney Fund ambassador and bodybuilder
Thus, instead of letting the wave propagate through the fuel, the fuel itself is moved through a largely stationary burn wave. This is contrary to many media reports, which have popularized the concept as a candle-like reactor with a burn region that moves down a stick of fuel. By replacing a static core configuration with an actively managed "standing wave" or "soliton" core, TerraPower's design avoids the problem of cooling a highly variable burn region. Under this scenario, the reconfiguration of fuel rods is accomplished remotely by robotic devices; the containment vessel remains closed during the procedure, and there is no associated downtime. In a separate fast-reactor project, the NRC approved a construction permit for TerraPower's Natrium project at Kemmerer, Wyoming, in March 2026. The sodium-cooled fast reactor still required a separate operating licence before it could operate.
David Chalmers identified two problems in understanding the mind, which he named the "hard" and "easy" problems of consciousness. The easy problem is understanding how the brain processes signals, makes plans and controls behaviour. The hard problem is explaining how this feels or why it should feel like anything at all, assuming we are right in thinking that it truly does feel like something (Dennett's consciousness illusionism says this is an illusion). While human information processing is easy to explain, human subjective experience is difficult to explain. For example, it is easy to imagine a colour-blind person who has learned to identify which objects in their field of view are red, but it is not clear what would be required for the person to know what red looks like.
=== Monotreme research === Flannery et al. (2026) review the fossil record and evolutionary history of monotremes. Chimento (2026) reports evidence of similarities of morphology of teeth and mandibles of monotremes, meridiolestidans and dryolestoids from Northern Hemisphere, and interprets the available data as consistent with origin of monotreme dental pattern from teeth of Gondwanan dryolestoids. Ziegler & Lockett (2026) report the discovery of a skull of Megalibgwilia owenii from the Foul Air Cave in the Buchan Caves Reserve, representing the first record of the species from Victoria (Australia).
Sources: en.wikipedia.org
=== Neuropathy and neurological diseases === Abnormal expression of CK1δ in brain tissue has been found in many diseases by immunohistochemistry and gene expression studies, like Alzheimer's disease, Down syndrome, progressive supranuclear palsy, parkinsonism dementia complex of Guam (PDC), Pick's disease, pallido-ponto-nigral degeneration (PPND) and Familial advanced sleep phase syndrome. In typical pathological tissues neuritic plaques (NPs) or granulovacuolar degeneration bodies (GVBs) of AD show high expression of CK1δ, whereas in neurofibrillary tangles (NFTs) expression of CK1δ is low. The AD hallmark proteins tau in NFTs or GVBs and TAR DNA-binding protein of 43 kDa (TDP-43) in GVBs colocalize with CK1δ. In vitro phosphorylation studies revealed that several sites within tau and TDP-43 were phosphorylated by CK1δ. Reduction of site-specific phosphorylation of TDP-43 by inhibition of CK1δ in both, a neuronal cell model as well as in a Drosophila model resulted in prevention of neurotoxicity and consequently to rescue of cells from cell death. Based on these studies, CK1δ could be recognized as a hallmark as well as a potential target for AD treatment and may be further useful for diagnostic and therapeutic purpose in the future. In addition, CK1δ plays a regulatory role in Parkinson's disease (PD) by phosphorylating α-synuclein. Familial advanced sleep phase syndrome (FASPS) is another neurological disease associated with CK1δ-mediated phosphorylation of the mammalian clock protein PER2.
==== Return to government in 2023 ==== Lad was re-elected from Kalaghatgi in the 2023 Karnataka Assembly election and was inducted into Siddaramaiah's cabinet on 27 May 2023 as Minister for Labour. He was also appointed minister in charge of Dharwad district in June 2023.
After a period of rest and recovery, Zita found herself regularly going back to Europe for the weddings of her children. She decided to move back to the continent full-time in 1952 to Luxembourg to look after her aging mother. Maria Antonia died at the age of 96 in 1959. The bishop of Chur proposed to Zita that she move into a residence that he administered (formerly a castle of the Counts de Salis) at Zizers, Graubünden in Switzerland. As the castle had enough space for visits from her large family and a nearby chapel (a necessity for the devoutly-Catholic Zita), she accepted with ease. Zita occupied herself in her final years with her family. Although the restrictions on the Habsburgs entering Austria had been lifted, that applied only to those born after 10 April 1919. That meant that Zita could not attend the funeral of her daughter Adelheid in 1971, which was painful for her. She also involved herself in the efforts to have her deceased husband, the "Peace Emperor" canonised. In 1982, the restrictions were eased, and she returned to Austria after being absent for six decades. Over the next few years, the Empress made several visits to her former Austrian homeland and even appeared on Austrian television. In a series of interviews with the Viennese tabloid newspaper Kronen Zeitung, Zita expressed her belief that the deaths of Crown Prince Rudolf of Austria and his mistress Baroness Mary Vetsera, at Mayerling, in 1889, were not a double suicide but rather murder by French or Austrian agents.
=== Meiosis === Meiotic recombination in D. melanogaster appears to be employed in repairing damage in germ-line DNA as indicated by the findings that meiotic recombination is induced by the DNA damaging agents ultraviolet light and mitomycin C.
=== Recreational === The perceived effects are said to resemble those of 3-MMC, users report reduced effects and a shorter duration in comparison. Effects include stimulation, euphoria, and increased confidence, libido, and sociability. It can be administered orally or through nasal insufflation. As with other stimulant drugs, rectal and intravenous administration is also possible. The acute effects of 3-CMC last 1 to 4 hours, depending on the administration method. After effects, like difficulty sleeping, can last 3 to 12 hours longer.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.